

Literaturverzeichnis

Hamburger Ärzteblatt 03 | 2025

Seite 1

Weidestr. 122 b

22083 Hamburg

Redaktion

E-Mail: verlag@aeckhh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

S. 12 – 17: Die Leber im Visier des Immunsystems. Von Dr. Silja Steinmann, Dr. Jan Philipp Weltzsch, Prof. Dr. Ansgar W. Lohse

1. Willame C, Dodd C, van der Aa L, Picelli G, Emborg HD, Kahlert J et al. Incidence Rates of Autoimmune Diseases in European Healthcare Databases: A Contribution of the ADVANCE Project. *Drug Saf* 2021;44:383. <https://doi.org/10.1007/S40264-020-01031-1>.
2. Sebode M, Kloppenburg A, Aigner A, Lohse AW, Schramm C, Linder R. Population-based study of autoimmune hepatitis and primary biliary cholangitis in Germany: rising prevalences based on ICD codes, yet deficits in medical treatment. *Z Gastroenterol* 2020;58:431–8. <https://doi.org/10.1055/A-1135-9306>.
3. Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. *J Hepatol* 2023;79:516–37. <https://doi.org/10.1016/j.jhep.2023.03.017>
4. Steinmann S, Hartl J, Weidemann S, Füssel K, Kroll C, Sebode M et al. Accuracy of controlled attenuation parameter measurement for the detection of steatosis in autoimmune liver diseases. *JHEP Reports* 2023;5:100898. <https://doi.org/10.1016/J.JHEPR.2023.100898>.
5. Smyk DS, Rigopoulou EI, Pares A, Billinis C, Burroughs AK, Muratori L et al. Sex differences associated with primary biliary cirrhosis. *Clin Dev Immunol* 2012;2012. <https://doi.org/10.1155/2012/610504>.
6. Schwinge D, Schramm C. Sex-related factors in autoimmune liver diseases. *Semin Immunopathol* 2019;41:165–75. <https://doi.org/10.1007/S00281-018-0715-8>.
7. Schramm C, Kanzler S, Meyer zum Büschenfelde K-H, Galle PR, Lohse AW. Autoimmune hepatitis in the elderly. *Am J Gastroenterol* 2001;96:1587–91. <https://doi.org/10.1111/J.1572-0241.2001.03782.X>.
8. Mantaka A, Koulentaki M, Chlouverakis G, Enele-Melono JM, Darivianaki A, Tzardi M et al. Primary Biliary Cirrhosis in a genetically homogeneous population: Disease associations and familial occurrence rates. *BMC Gastroenterol* 2012;12:1–8. <https://doi.org/10.1186/1471-230X-12-110>.
9. Allocca M, Crosignani A, Gritti A, Ghilardi G, Gobatti D, Caruso D et al. Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis. *Gut* 2006;55:1795–800. <https://doi.org/10.1136/GUT.2005.079814>.
10. Seltene Lebererkrankungen (LeiSe LebEr) - DGVS - Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten n.d. <https://www.dgvs.de/leitlinien/leber-galle-pankreas/seltene-lebererkrankungen-leise-leber/> (accessed January 4, 2025).
11. Duan W, Chen S, Li S, Lv T, Li B, Wang X et al. The future risk of primary biliary cholangitis (PBC) is low among patients with incidental anti-mitochondrial antibodies but without baseline PBC. *Hepatol Commun* 2022;6:3112–9. <https://doi.org/10.1002/HEP4.2067>.
12. Nakanuma Y, Ohta G. Quantitation of hepatic granulomas and epithelioid cells in primary biliary cirrhosis. *Hepatology* 1983;3:423–7. <https://doi.org/10.1002/HEP.1840030323>.
13. Horst LJ, Weidemann S, Lohse AW, Sebode M. Hepatic granuloma-A diagnostic challenge . *Z Rheumatol* 2022;81:567–76. <https://doi.org/10.1007/S00393-022-01235-Z>.
14. Corpechot C, Lemoinne S, Soret PA, Hansen B, Hirschfield G, Gulamhusein A et al. Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain? *Hepatology* 2024;79:39–48. <https://doi.org/10.1097/HEP.0000000000000529>.

Literaturverzeichnis

Hamburger Ärzteblatt 03 | 2025

Seite 2

Weidestr. 122 b

22083 Hamburg

Redaktion

E-Mail: verlag@aekhh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

15. Murillo Perez CF, Harms MH, Lindor KD, Van Buuren HR, Hirschfield GM, Corpechot C et al. Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. *Am J Gastroenterol* 2020;115:1066–74. <https://doi.org/10.14309/AJG.0000000000000557>.
16. Kowdley KV, Hirschfield GM, Coombs C, Malecha ES, Bessonova L, Li J et al. COBALT: A Confirmatory Trial of Obeticholic Acid in Primary Biliary Cholangitis With Placebo and External Controls. *American Journal of Gastroenterology* 2024. <https://doi.org/10.14309/AJG.00000000000003029>.
17. Hirschfield GM, Bowlus CL, Mayo MJ, Kremer AE, Vierling JM, Kowdley KV. et al. A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis. *N Engl J Med* 2024;390:783–94. <https://doi.org/10.1056/NEJMoa2312100>.
18. Kowdley KV, Bowlus CL, Levy C, Akarca US, Alvares-da-Silva MR, Andreone P et al. Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis. *N Engl J Med* 2024;390:795–805. <https://doi.org/10.1056/NEJMoa2306185>.
19. Karlsen TH, Folseraas T, Thorburn D, Vesterhus M. Primary sclerosing cholangitis - a comprehensive review. *J Hepatol* 2017;67:1298–323. <https://doi.org/10.1016/J.JHEP.2017.07.022>.
20. Ponsioen CY, Assis DN, Boberg KM, Bowlus CL, Deneau M, Thorburn D et al. Defining Primary Sclerosing Cholangitis: Results From an International Primary Sclerosing Cholangitis Study Group Consensus Process. *Gastroenterology* 2021;161:1764–1775. e5. <https://doi.org/10.1053/J.GASTRO.2021.07.046>.
21. Boonstra K, Weersma RK, van Erpecum KJ, Rauws EA, Spanier BWM, Poen AC et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. *Hepatology* 2013;58:2045–55. <https://doi.org/10.1002/HEP.26565>.
22. Eaton JE, Thackeray EW, Lindor KD. Likelihood of malignancy in gallbladder polyps and outcomes following cholecystectomy in primary sclerosing cholangitis. *Am J Gastroenterol* 2012;107:431–9. <https://doi.org/10.1038/AJG.2011.361>.
23. Hahn JW, Yang HR, Moon JS, Chang JY, Lee K, Kim GA, et al. Global incidence and prevalence of autoimmune hepatitis, 1970–2022: a systematic review and meta-analysis. *EClinicalMedicine* 2023;65:102280. <https://doi.org/10.1016/j.eclim.2023.102280>.
24. Lohse AW, Mieli-Vergani G. Autoimmune hepatitis. *J Hepatol* 2011;55:171–82. <https://doi.org/10.1016/j.jhep.2010.12.012>.
25. Hartl J, Wehmeyer M, Alali S, Sebode M, Weidemann S, Ptashynska A et al. Right and left liver lobe biopsies by minilaparoscopy reveal clinically significant sampling error in staging and grading of autoimmune hepatitis. *Liver International* 2023;43:1269–76. <https://doi.org/10.1111/liv.15583>.
26. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F et al. Histological grading and staging of chronic hepatitis. *J Hepatol* 1995;22:696–9. [https://doi.org/10.1016/0168-8278\(95\)80226-6](https://doi.org/10.1016/0168-8278(95)80226-6).
27. Galaski J, Weiler-Normann C, Schakat M, Zachou K, Muratori P, Lampalzer S et al. Update of the simplified criteria for autoimmune hepatitis: Evaluation of the methodology for immunoserological testing. *J Hepatol* 2021;74:312–20. <https://doi.org/10.1016/j.jhep.2020.07.032>.
28. Hartl J, Ehlken H, Sebode M, Peiseler M, Krech T, Zenouzi R et al. Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis. *J Hepatol* 2018;68:754–63. <https://doi.org/10.1016/j.jhep.2017.11.020>.
29. Pape S, Gevers TJG, Belias M, Mustafajev IF, Vrolijk JM, van Hoek B et al. Predniso(l)o)ne Dosage and Chance of Remission in Patients With Autoimmune Hepatitis. *Clinical Gastroenterology and Hepatology* 2019;17:2068–2075.e2. <https://doi.org/10.1016/j.cgh.2018.12.035>.

Literaturverzeichnis

Hamburger Ärzteblatt 03 | 2025

Seite 3

Weidestr. 122 b

22083 Hamburg

Redaktion

E-Mail: verlag@aekhh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

30. Weiler-Normann C, Schramm C, Quaas A, Wiegard C, Glaubke C, Pannicke N et al. Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. *J Hepatol* 2013;58:529–34. <https://doi.org/10.1016/j.jhep.2012.11.010>.
31. Weltzsch JP, Bartel CF, Waldmann M, Renné T, Schulze S, Terzioli Beretta-Piccoli B et al. Optimizing thiopurine therapy in autoimmune hepatitis: A multi-center study on monitoring metabolite profiles and co-therapy with allopurinol. *Hepatology* 2024. <https://doi.org/10.1097/HEP.0000000000000940>.
32. Plagiannakos CG, Hirschfield GM, Lytvynak E, Roberts SB, Ismail M, Gulamhusein AF et al. Treatment response and clinical event-free survival in autoimmune hepatitis: A Canadian multicentre cohort study. *J Hepatol* 2024;81:227–37. <https://doi.org/10.1016/j.jhep.2024.03.021>.

Angaben zu möglichen Interessenkonflikten: vorhanden

1. Silja Steinmann: Vortragstätigkeit im Rahmen von Hepatologiekurses, der von Falk gesponsort wird
2. Ansgar W Lohse: Beratungstätigkeit für Servier und Kezar Life Science sowie Vortragstätigkeit für die Falk Foundation und die Durchführung des Hepatologiekurses, der von Falk gesponsort wird.

S. 29: Bilder aus der klinischen Medizin: Spaß unter Freunden. *Von Dr. Jan Ulrich, Hon. Prof. Dr. Dietmar E. Kivelitz*

1. Katsinelos P et al. Endoscopic techniques and management of foreign body ingestion and food bolus impaction in the upper gastrointestinal tract: a retrospective analysis of 139 cases. *J Clin Gastroenterol* 2006; 40(9):784–9. doi: 10.1097/01.mcg.0000225602.25858.2c.
2. Miller K, Waye JD. Polyp retrieval after colonoscopic polypectomy: use of the Roth Retrieval Net. *Gastrointest Endosc* 2001; 54(4):505–7. doi: 10.1067/mge.2001.118255.

S. 30 – 32: Therapieoptionen beim Urothelkarzinom des oberen Harntrakts. *Von Prof. Dr. Michael Rink*

1. Roupret M, Gontero P, Birtle A, Compérat EM, Dominguez-Escrí JL, F. Liedberg et al. EAU Guidelines on Upper Urinary Tract Urothelial Carcinoma. EAU Guidelines Edn presented at the EAU Annual Congress Milan 2023 ISBN 978-94-92671-19-6. 2023.
2. Green DA, Rink M, Xylinas E, Matin SF, Stenzl A, Roupret M et al. Urothelial carcinoma of the bladder and the upper tract: disparate twins. *J Urol.* 2013;189:1214-21.
3. Rink M, Adam M, Hansen J, Chun FK, Ahyai SA, Remzi M et al. Upper tract urothelial carcinoma. An update on clinical and pathological prognostic factors. *Urologe A.* 2012;51:1228-39.
4. van Doeveren T, van der Mark M, van Leeuwen PJ, Boormans JL, Aben KK. Rising incidence rates and unaltered survival rates for primary upper urinary tract urothelial carcinoma: a Dutch population-based study from 1993 to 2017. *BJU Int.* 2021;128:343-51.
5. Darr C, Hadaschik BA, Tschirdehn S. Systemic treatment of metastatic tumors of the upper urinary tract. *Urologe A.* 2019;58:30-3.
6. Janisch F, Shariat SF, Baltzer P, Fajkovic H, Kimura S, Iwata T et al. Diagnostic performance of multidetector computed tomographic (MDCTU) in upper tract urothelial carcinoma (UTUC): a systematic review and meta-analysis. *World J Urol.* 2020;38:1165-75.
7. Tavora F, Fajardo DA, Lee TK, Lotan T, Miller JS, Miyamoto H et al. Small endoscopic biopsies of the ureter and renal pelvis: pathologic pitfalls. *Am J Surg Pathol.* 2009;33:1540-6.

Literaturverzeichnis

Hamburger Ärzteblatt 03 | 2025

Seite 4

Weidestr. 122 b
22083 Hamburg
Redaktion
E-Mail: verlag@aeckhh.de
Tel.: (040) 20 22 99 – 205
Fax: (040) 20 22 99 – 400

8. Grahn A, Melle-Hannah M, Malm C, Jaderling F, Radecka E, Beckman M, et al. Diagnostic accuracy of computed tomography urography and visual assessment during ureterorenoscopy in upper tract urothelial carcinoma. *BJU Int.* 2017;119:289-97.
9. Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. *Cancer.* 2009;115:1224-33.
10. Konig F, Shariat SF, Karakiewicz PI, Mun DH, Rink M, Pradere B. Quality indicators for the management of high-risk upper tract urothelial carcinoma requiring radical nephroureterectomy. *Curr Opin Urol.* 2021;31:291-6.
11. Dominguez-Escrig JL, Peyronnet B, Seisen T, Bruins HM, Yuan CY, Babjuk M et al. Potential Benefit of Lymph Node Dissection During Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the European Association of Urology Guidelines Panel on Non-muscle-invasive Bladder Cancer. *Eur Urol Focus.* 2019;5:224-41.
12. Tinay I, Gelpi-Hammerschmidt F, Leow JJ, Allard CB, Rodriguez D, Wang Y et al. Trends in utilisation, perioperative outcomes, and costs of nephroureterectomies in the management of upper tract urothelial carcinoma: a 10-year population-based analysis. *BJU Int.* 2016;117:954-60.
13. Vecchia A, Carbonara U, Djaladat H, Mehazin R, Eun DD, Reese AC et al. Robotic vs Laparoscopic Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Multicenter Propensity-Score Matched Pair "tetrafecta" Analysis (ROBUUST Collaborative Group). *J Endourol.* 2022;36:752-9.
14. Simone G, Papalia R, Guaglianone S, Ferriero M, Leonardo C, Forastiere E et al. Laparoscopic versus open nephroureterectomy: perioperative and oncologic outcomes from a randomised prospective study. *Eur Urol.* 2009;56:520-6.
15. Miller DC, Schonlau M, Litwin MS, Lai J, Saigal CS. Urologic Diseases in America P. Renal and cardiovascular morbidity after partial or radical nephrectomy. *Cancer.* 2008;112:511-20.
16. Jeldres C, Sun M, Isbarn H, Lughezzani G, Budaus L, Alasker A et al. A population-based assessment of perioperative mortality after nephroureterectomy for upper-tract urothelial carcinoma. *Urology.* 2010;75:315-20.
17. Gallioli A, Boissier R, Territo A, Vila Reyes H, Sanguedolce F, Gaya JM et al. Adjuvant Single-Dose Upper Urinary Tract Instillation of Mitomycin C After Therapeutic Ureteroscopy for Upper Tract Urothelial Carcinoma: A Single-Centre Prospective Non-Randomized Trial. *J Endourol.* 2020;34:573-80.
18. Margulis V, Puligandla M, Trabulsi EJ, Plimack ER, Kessler ER, Matin SF et al. Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extrirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma. *J Urol.* 2020;203:690-8.
19. Leow JJ, Chong YL, Chang SL, Valderrama BP, Powles T, Bellmunt J. Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy. *Eur Urol.* 2021;79:635-54.
20. Birtle A, Johnson M, Chester J, Jones R, Dolling D, Bryan RT et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. *Lancet.* 2020;395:1268-77.
21. Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. *N Engl J Med.* 2021;384:2102-14.
22. Galsky MD, Witjes JA, Gschwend JE, Milowsky MI, Schenker M, Valderrama BP et al. Extended follow-up from CheckMate 274 including the first report of overall survival outcomes. *EAU 2024 Congress* (Paris, France, April 5-8 2024). 2024.

Angaben zu möglichen Interessenkonflikten: keine

Literaturverzeichnis

Hamburger Ärzteblatt 03 | 2025

Seite 5

Weidestr. 122 b
22083 Hamburg
Redaktion
E-Mail: verlag@aeckhh.de
Tel.: (040) 20 22 99 – 205
Fax: (040) 20 22 99 – 400

S. 34 – 35: Der besondere Fall: Vaskulitische Infarkte bei Neuroborreliose.

Von Dr. Pia Flüthmann, PD Dr. Till Illies, Prof. Dr. Joachim Röther

1. Rupprecht TA, Plate A, Adam M, Wick M, Kastenbauer S, Schmidt C, Klein M, Pfister HW, Koedel U. The chemokine CXCL13 is a key regulator of B cell recruitment to the cerebrospinal fluid in acute Lyme neuroborreliosis. *J Neuroinflammation*. 2009 Dec 30;6:42. doi: 10.1186/1742-2094-6-42. PMID: 20042073; PMCID: PMC2811704.
2. Schmidt C, Plate A, Angele B, Pfister HW, Wick M, Koedel U, Rupprecht TA. A prospective study on the role of CXCL13 in Lyme neuroborreliosis. *Neurology*. 2011 Mar 22;76(12):1051-8. doi: 10.1212/WNL.0b013e318211c39a. PMID: 21422457.
3. Rauer S, Kastenbauer S et al. Neuroborreliose, S3-Leitlinie, 2024; in: Deutsche Gesellschaft für Neurologie (Hrsg.), Leitlinien für Diagnostik und Therapie in der Neurologie. Online: www.dgn.org/leitlinien (abgerufen am 22.08.2024)
4. Romi F, Kråkenes J, Aarli JA, Tysnes OB. Neuroborreliosis with vasculitis causing stroke-like manifestations. *Eur Neurol*. 2004;51(1):49-50. doi: 10.1159/000075090. Epub 2003 Nov 21. PMID: 14639033.
5. Back T, Grünig S, Winter Y, Bodechtel U, Guthke K, Khati D, von Kummer R. Neuroborreliosis-associated cerebral vasculitis: long-term outcome and health-related quality of life. *J Neurol*. 2013 Jun;260(6):1569-75. doi: 10.1007/s00415-013-6831-4. Epub 2013 Jan 18. PMID: 23329377.
6. Haene A, Tröger M. Diffuse hyperintense brainstem lesions in neuroborreliosis. *Neurology*. 2009 Jul 28;73(4):326. doi: 10.1212/WNL.0b013e3181af78cc. PMID: 19636055.
7. Pfefferkorn T, Röther J, Eckert B, Janssen H. Brainstem encephalitis in neuroborreliosis: typical clinical course and distinct MRI findings. *J Neurol*. 2021 Feb;268(2):502-505. doi: 10.1007/s00415-020-10188-9. Epub 2020 Aug 28. PMID: 32857263.
8. Dersch R, Sommer H, Rauer S, Meerpohl JJ. Prevalence and spectrum of residual symptoms in Lyme neuroborreliosis after pharmacological treatment: a systematic review. *J Neurol*. 2016 Jan;263(1):17-24. doi: 10.1007/s00415-015-7923-0. Epub 2015 Oct 12. PMID: 26459093.